Letter from the Editor

I am proud to present this year’s Medicom coverage of the 19th IASLC World Conference on Lung Cancer (WCLC).

Only ten years ago, we still needed a meta-analysis to prove modest benefit of chemotherapy over best supportive care in advanced non-small-cell lung cancer. Now, we have experienced substantial progress in lung cancer treatment, leading to better understanding of the molecular biology, driver mutations, mechanisms of resistance, and the major impact of immunotherapy. As the landscape becomes more and more complex, it becomes a challenge to keep up with rapidly changing standards and new developments.

This year’s WCLC in Toronto offers exciting new data, broadening our knowledge in screening, diagnostic tools, and clinically significant, practice-changing treatments in lung cancer, among others.

We hope to contribute by keeping you updated with our fast, peer-reviewed conference highlights. Sincerely yours, Stefan Rauh

PS : ESMO guidelines on advanced non-small-cell lung cancer have been updated very recently and may provide you with a valuable tool in your daily treatment decisions. You may access them via the website www.esmo.org.

Biography

Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is Chair of the ESMO Practicing Oncologist’s Working Group since 2015, member of the ESMO Quality Task Force, extended member of the ESMO Public Policy Committee, Assistant Editor of ESMO Cancer Horizons, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.



Posted on 21 November 20189 March 2021